Article Text

Download PDFPDF

LO-020 Association between corticosteroid use and risk of avascular necrosis in patients with systemic lupus erythematosus: a nested case-control study
  1. Jongmin Lee1,
  2. Seung-Hun You1,
  3. Yu-Seon Jung1,
  4. Yoon-Kyoung Sung2,3,
  5. Soo-Kyung Cho2,3 and
  6. Sun-Young Jung1
  1. 1Department of Global Innovative Drugs, Colleage of Pharmacy, Chung-Ang University, Republic of Korea
  2. 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
  3. 3Hanyang University, Institute for Rheumatology Research, Republic of Korea


Background Corticosteroid (CS) is effective for controlling inflammatory reactions in SLE, but may have been known to increase risk of avascular necrosis (AVN) in patients with Systemic lupus erythematosus (SLE). This population-based study aims to investigate the association between cumulative dose of CS and the incidence of AVN in newly diagnosed SLE patients.

Methods We conducted a nested case-control study using Korean National Health Insurance claims database from 2002 to 2018. Cohort of incident diagnosis of SLE (ICD10, M32) with rare intractable disease code (V136) were identified during 2007~2018. Cases, who were diagnosed for any reason with AVN (M87.0x, M87.1x, M87.3x, M87.8x, M87.9x, M90.5x (ICD-10)), were matched up to 10 controls based on gender, age (±5yrs), and date of SLE diagnosis (±6 months). Conditional logistic regression analysis was performed to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of AVN occurrence associated with cumulative dose of CS [prednisolone-equivalent dose (PED)] from the date of SLE diagnosis to the index date, with adjusting for hypertension, dyslipidemia, immunosuppressants and so forth. Cumulative CS dose was categorized into 3 groups (0≤ < 4g, 4≤ <8g and 8g≤) based on distribution in the study population.

Results Among the 12,375 SLE patients who were newly diagnosed during the inclusion period, a total of 358 AVN patients were identified. Controls without AVN (N=3,276) were identified. In terms of cumulative CS dose, used after first diagnosis of SLE, compared with cumulative CS dose less than 4g, ORs associated with 4≤ <8g and 8g≤ group were 2.48 (95% CI 1.70 – 3.64) and 6.14 (95% CI 4.20 – 8.93), respectively.

Conclusions The trend of association between higher cumulative CS dose and risk of AVN may provide evidence for monitoring patients with continuous use of CS for SLE management, especially in aspect of cumulative dose of CS.

  • SLE
  • AVN
  • corticosteroid

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.